Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

Psychiatria Polska is a distinguished journal published by WYDAWNICZY POLSKIEGO TOWARZYSTWA, focused on advancing the field of psychiatry and mental health. Established in 1967, this journal has become a vital resource for researchers, clinicians, and students, contributing to the understanding of psychiatric disorders and their treatments. With an ISSN of 0033-2674, it features a diverse range of studies, case reports, and reviews, making it an essential platform for sharing innovative findings within the psychiatric community. Although currently categorized in the Q3 quartile for both Medicine (miscellaneous) and Psychiatry and Mental Health in 2023, its increasing impact is evidenced by its Scopus ranking of #345 out of 567 in its category, placing it in the 39th percentile. Located in Cracow, Poland, Psychiatria Polska continues to foster international collaboration and knowledge exchange, despite being non-open access, ensuring that its high-quality content reaches a wide audience. This journal is dedicated to enhancing the dialogue on mental health, making it an indispensable resource for those committed to improving psychiatric practice and research.

EUROPEAN PSYCHIATRY, published by Cambridge University Press, stands at the forefront of advancements in the field of psychiatry and mental health, serving as a vital resource for researchers, professionals, and students alike. With an impressive Q1 ranking in Psychiatry and Mental Health and an impact factor that underscores its significance, this journal fosters innovative studies and discussions that shape contemporary understanding of mental health issues. Offering Open Access since 2020, it ensures that high-quality research is readily available to a global audience, bridging gaps in knowledge dissemination. The journal, which has been publishing since 1991, encompasses a broad range of topics relevant to mental health, emphasizing evidence-based practices and interdisciplinary approaches to treatment and care. With its ongoing commitment to excellence, EUROPEAN PSYCHIATRY continues to be an indispensable platform for advancing the science of mental health.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

ACTAS ESPANOLAS DE PSIQUIATRIA, published by the renowned JUAN JOSE LOPEZ-IBOR FOUNDATION, serves as a vital resource in the field of psychiatry and mental health, particularly within the Spanish-speaking academic community. With its ISSN 1139-9287 and E-ISSN 1578-2735, this journal has been a critical platform for disseminating high-quality research since its inception in 1996 and continues to contribute valuable insights until 2024. As a recognized journal in the Q3 category of psychiatry and mental health, it ranks 387 out of 567 in Scopus, placing it within the 31st percentile, thereby indicating a growing influence among its peers. The journal’s open access options enhance its accessibility, encouraging a broader readership to engage with contemporary research issues in mental health. Researchers, professionals, and students alike will find ACTAS ESPANOLAS DE PSIQUIATRIA essential for staying informed on the latest developments and innovations in psychiatric practice and research.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Alpha Psychiatry, published by AVES, stands at the forefront of mental health research and psychiatric advancements. With a commitment to disseminating high-quality and impactful studies, this journal serves as a critical platform for scholars, clinicians, and students interested in exploring the complexities of psychiatric disorders and treatment methodologies. Although the impact factor and specific scope details are still evolving, Alpha Psychiatry is dedicated to fostering interdisciplinary dialogue and promoting innovative research that tackles contemporary challenges in the field of psychiatry. As an open-access journal, it ensures that research is widely accessible, enhancing knowledge transfer and collaboration within the global scientific community. Located in Istanbul, Turkiye, the journal proudly represents a rich academic tradition, aiming to contribute significantly to the global discourse on mental health.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

PSYCHIATRY RESEARCH-NEUROIMAGING, published by Elsevier Ireland Ltd, stands at the intersection of neuroscience, psychiatry, and medical imaging, specializing in the latest advancements in neuroimaging techniques and their applications in psychiatric research. With a robust history since 1990, this esteemed journal features original research, reviews, and case studies that contribute significantly to the understanding of brain function in mental health disorders. Holding a notable Impact Factor and classified in Q2 for the fields of Neuroscience and Psychiatry and Q1 for Radiology, it serves as a vital resource for scholars and practitioners seeking to advance their knowledge in these domains. The journal is indexed in major databases, enhancing visibility and accessibility for global researchers. While it currently does not follow an open-access model, its reputable standing in Scopus ranks, alongside its targeted scope, makes it indispensable for those invested in neuroimaging research and its implications in psychiatry.

HARVARD REVIEW OF PSYCHIATRY is a prestigious academic journal focused on the field of psychiatry and mental health, published by Lippincott Williams & Wilkins. Established in 1993, this journal has become a critical resource for researchers, clinicians, and students alike, providing cutting-edge insights and scholarly articles that address contemporary issues in mental health. With an impressive impact factor reflected in its Q1 ranking in Psychiatry and Mental Health, the journal ranks #90 out of 567 in its category in Scopus, placing it in the top 16% of publications in this field. The journal is dedicated to disseminating high-quality research and fostering dialogue among professionals, thus contributing significantly to the advancement of psychiatric sciences. Researchers can access the journal through traditional subscriptions, ensuring that vital knowledge and innovative practices are shared among a global audience.